European Heart Journal Advance Access published online on August 17, 2005
European Heart Journal, doi:10.1093/eurheartj/ehi459
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Division of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, 900 S Limestone, 326 Wethington Building, Lexington, KY 40536-0200, USA
* To whom correspondence should be addressed. Aims Compared with placebo, abciximab has been associated with mortality reduction at late follow-up. The TARGET trial was performed to test whether tirofiban and abciximab provide similar efficacy outcomes among patients undergoing non-emergent, stent-based percutaneous coronary intervention. We report here the 1-year mortality of the study population. Methods and results In 18 countries at 149 hospitals, 4809 patients undergoing elective or urgent stent implantation were randomly assigned a bolus and infusion of tirofiban or abciximab. Ischaemic events were assessed at 30 days and 6 months and mortality was assessed at 1 year. We previously reported that abciximab was superior to tirofiban considering the composite rate of death or myocardial infarction at 30 days among all patients and at 6 months among those with an acute coronary syndrome (ACS). At 1-year follow-up death occurred in 46 (1.9%) patients who received tirofiban and 42 (1.7%) patients who received abciximab (hazard ratio 1.10, 95% CI 0.72-1.67; P = 0.660). Mortality rates for patients with ACS were 2.3% with tirofiban vs. 2.2% with abciximab (hazard ratio 1.03, 95% CI 0.64-1.67; P = 0.897) and those without ACS were 1.4 vs. 1.0% (hazard ratio 1.32, 95% CI 0.56-3.13; P = 0.530). Conclusion At 1 year, tirofiban provided a similar level of survival benefit compared with abciximab.
Received May 12, 2005
Revised June 30, 2005
Accepted July 25, 2005
Clinical research
Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up
2 Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH, USA
3 Hôpital Cardiologique, Lille, France
4 Skejby Hospital, Aarhus University Hospital, Brendstrupgaardsvej, Denmark
5 University of Pennsylvania Medical Center, Philadelphia, PA, USA
6 Herz-Zentrum Bad Krozingen, Bad Krozingen, Germany
7 Riverside Methodist Hospital, Columbus, OH, USA
8 Jean-Minjoz Hospital, Besançon, France
9 Columbia University Medical Center, New York, NY, USA
10 Università Degli Studi di Parma, Parma, Italy
Debabrata Mukherjee, E-mail: mukherjee{at}uky.edu
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Valgimigli, G. Biondi-Zoccai, M. Tebaldi, A. W.J. van 't Hof, G. Campo, C. Hamm, J. ten Berg, L. Bolognese, F. Saia, G. B. Danzi, et al. Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials Eur. Heart J., September 14, 2009; (2009) ehp376v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Gitt and A. Betriu Antiplatelet therapy in acute coronary syndromes Eur. Heart J. Suppl., January 1, 2008; 10(suppl_A): A4 - A12. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Bode and K. Huber Antiplatelet therapy in percutaneous coronary intervention Eur. Heart J. Suppl., January 1, 2008; 10(suppl_A): A13 - A20. [Abstract] [Full Text] [PDF]
|
|